Mesa Laboratories Inc. announced its financial results for the fourth fiscal quarter (4Q26) and fiscal year (FY26) ending March 31, 2026. The company reported a 2.6% increase in revenues for the quarter and a 3.4% increase for the full year compared to the previous periods.
Operating income rose significantly by 87% in 4Q26, reaching $2,748, while for the entire fiscal year, it increased 13.3% to $18,511. The company also repaid $14,700 in debt, lowering its total net leverage ratio to 2.11.
In his commentary, President and CEO Siddhartha Kadia expressed optimism about the company’s potential to create shareholder value and emphasized ongoing assessments of business operations during his initial onboarding period. CFO John Sakys highlighted growth in revenues despite challenges in the Biopharmaceutical Development sector due to export control issues. He anticipated a return to positive growth in core organic revenues in the upcoming quarter.
For the fourth quarter, Mesa’s Sterilization and Disinfection Control division, which represented 46% of revenues, achieved an organic growth of 17.7%. However, the Biopharmaceutical Development division faced a substantial decline in revenues of 29.9% in the same period.
Overall, the results showcase Mesa Laboratories’ resilience and adaptation to market challenges, with a focus on maintaining profitability and reducing debt.
The primary source was Globe Newswire.